Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 10/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | GNMT | Q14749 | 2/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.55 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7813911 | 0.84 | ADORA1 (0.55) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL1332746 | 0.84 | P2RY2 (0.55) | AHCYHIF1ATMEM97SIGMAR1 | |
| SCHEMBL24478703 | 0.81 | PRMT5 (0.73) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL2117335 | 0.81 | AHCY (0.68) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL29385449 | 0.81 | AHCY (0.68) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL1757011 | 0.81 | AHCY (0.68) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL31680251 | 0.80 | AHCY (0.68) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL397800 | 0.80 | AHCY (0.68) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL6902911 | 0.80 | AHCY (0.67) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 | |
| SCHEMBL6902895 | 0.80 | AHCY (0.67) | AHCYHIF1ATMEM97SIGMAR1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030230-B2 | Process of purifying phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | claimed |
| WO-2004039469-A2 | PROCESS OF PURIFYING PHOSPHORAMIDITES | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040082775-A1 | Process of purifying phosphoramidites | ISIS PHARMACEUTICALS INC. | 2004-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082775-A1 | Process of purifying phosphoramidites | PHOSPHO1, ADAR, POLRMT | AHCY 1196/4885HIF1A 4533/4885TMEM97 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.